Clinical Trial Search

Primary: Assessment of the Efficacy of Selumetinib in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine Measured as Progression Free Survival…

Primary: 12-week Abdominal Pain/Abdominal Discomfort Weekly Responder — 250; 206 Participants — p=0.0010

Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…

Primary: Mean Intravaginal Ejaculatory Latency Time (IELT): Change From Baseline to During 3 Month Double Blind-treatment — 4.607; 1.505 ratio — p=<0.0001

Primary: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs) — 75; 0; 0 percentage of participants

Primary: Disease-free Survival — 84.7; 86.6; 89 percentage of participants — p=0.1

Primary: Seroconversion to Vaccine Antigens Following Vaccination With Quadrivalent Vaccine — 66.7; 63.5; 72.1; 57.0 percentage of participants

Primary: Change From Baseline in Genant-modified Total Sharp Score (mTSS) — 7.00; 0 units on a scale — p=0.83

Primary: Overall Survival — 108; 124 participants

Primary: Percentage of Participants With Treatment-Related Adverse Events — 8.2 percentage of participants

Primary: Percent Change From Baseline in Triglyceride Level at the Final Visit — -10.93; -22.65; -11.30 percent change — p=0.8760

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 106; 110; 109 participants

Primary: Change From Baseline in the Weekly Itch Severity Score at Week 12 — -10.22; -8.80; -6.51 Units on a scale — p=<0.001

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 99.0; 0 percentage of participants — p=< 0.001

Primary: Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 12 Months — 0.39; -0.21; -2.2 percent change